Ublituximab

Tax included
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects.
MedChemExpress 
HY-P99538

Data sheet

Size
Multiple sizes
Reactivity
CD20
CAS
1174014-05-1